Canada markets closed
  • S&P/TSX

    19,290.98
    -19.76 (-0.10%)
     
  • S&P 500

    4,201.62
    +34.03 (+0.82%)
     
  • DOW

    34,548.53
    +318.19 (+0.93%)
     
  • CAD/USD

    0.8228
    +0.0075 (+0.92%)
     
  • CRUDE OIL

    64.96
    +0.25 (+0.39%)
     
  • BTC-CAD

    68,521.37
    -1,677.98 (-2.39%)
     
  • CMC Crypto 200

    1,468.60
    -2.81 (-0.19%)
     
  • GOLD FUTURES

    1,814.70
    -1.00 (-0.06%)
     
  • RUSSELL 2000

    2,241.42
    +0.05 (+0.00%)
     
  • 10-Yr Bond

    1.5610
    -0.0230 (-1.45%)
     
  • NASDAQ futures

    13,615.00
    +17.25 (+0.13%)
     
  • VOLATILITY

    18.39
    -0.76 (-3.97%)
     
  • FTSE

    7,076.17
    +36.87 (+0.52%)
     
  • NIKKEI 225

    29,331.37
    +518.77 (+1.80%)
     
  • CAD/EUR

    0.6817
    +0.0031 (+0.46%)
     

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN

  • Oops!
    Something went wrong.
    Please try again later.
Newsfile Corp.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - April 19, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc..

Shareholders who purchased shares of FGEN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

CONTACT US HERE:
https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=14879&from=5

CLASS PERIOD : November 8, 2019 to April 6, 2021

ALLEGATIONS : The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80968